Paclitaxel/ramucirumabGastrointestinal perforation and fatigue: 3 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2020年 / 1801卷 / 1期

关键词：

D O I：

10.1007/s40278-020-77867-8

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：207 / 207

相关论文

共 50 条

[31] Epirubicin/paclitaxel/potassiumExtravasation leading to necrosis: 3 case reports
Reactions Weekly, 2015, 1553 (1) : 134 - 134
[32] Tafluprost/timololBradycardia, dizziness and fatigue: 3 case reports
Reactions Weekly, 2022, 1918 (1) : 455 - 455
[33] BevacizumabGastrointestinal perforation: 2 case reports
Reactions Weekly, 2019, 1772 (1) : 74 - 74
[34] BevacizumabGastrointestinal perforation: 2 case reports
Reactions Weekly, 2023, 1942 (1) : 74 - 74
[35] AntineoplasticsBowel perforation: 4 case reports
Reactions Weekly, 2023, 1977 (1) : 32 - 32
[36] CabazitaxelBowel perforation: 2 case reports
Reactions Weekly, 2020, 1793 (1) : 114 - 114
[37] BevacizumabIntestinal perforation: 10 case reports
Reactions Weekly, 2010, 1313 (1) : 11 - 11
[38] Nivolumab/pembrolizumabOral mucositis and fatigue: 3 case reports
Reactions Weekly, 2021, 1871 (1) : 328 - 328
[39] AntineoplasticsColon perforation: 30 case reports
Reactions Weekly, 2021, 1840 (1) : 36 - 36
[40] AntineoplasticsGastric perforation: 6 case reports
Reactions Weekly, 2017, 1649 (1) : 36 - 36

← 1 2 3 4 5 →